CSL Limited (ASX:CSL) and this ASX healthcare share could be top options for Australian investors in 2021 and beyond…
The post 2 fantastic ASX healthcare shares to buy for 2021 appeared first on The Motley Fool Australia. –
Due to ageing populations, better technologies and treatments, and increasing chronic disease burden, demand for healthcare services is expected to continue to increase over the next few decades.
This bodes well for healthcare shares and has many tipping them to continue to outperform over the long term.
Two healthcare shares that are highly rated are listed below:
CSL Limited (ASX: CSL)
CSL is one of the world’s leading biotherapeutics companies. It is made up of the high quality CSL Behring and Seqirus businesses. CSL Behring is the global leader in plasma therapies and Seqirus is the second largest influenza vaccines business.
Both businesses have been growing at a solid rate in recent years and have been tipped to continue doing so in the future. This is due to their leading therapies and lucrative research and development pipelines.
CSL’s pipeline contains a number of highly promising products that have the potential to generate significant revenues in the future. This includes clazakizumab, which is being developed to treat kidney transplant rejection. This product alone could generate peak sales of US$5.4 billion eventually.
UBS recently retained its buy rating and $346.00 price target on CSL’s shares. This compares to the latest CSL share price of $304.14.
ResMed Inc. (ASX: RMD)
ResMed has been growing at a such a strong rate over the last decade it has now become one of the world’s leading sleep treatment companies. Pleasingly, it has started the new decade just as strongly as it finished the last. In FY 2020, it delivered a 15% increase in revenue to US$2,957 million and a 32% jump in net income to US$692.8 million.
The good news is that it has started FY 2021 strongly and appears well-placed to continue this positive form in the future. This is thanks to its world-class products and the massive number of undiagnosed sleep apnoea sufferers globally.
The company also has a rapidly growth digital health ecosystem, which reached over 12 million cloud connectable medical devices in 2020. This provides ResMed with strong recurring revenues and a material amount of high quality data.
Last month Credit Suisse put an outperform rating and $31.00 price target on ResMed’s shares. This compares to the current ResMed share price of $28.58.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
- 3 stellar ASX growth shares to buy
- CSL (ASX:CSL) share price on watch after hints of ‘far more robust’ vaccine
- 3 ASX growth shares to buy for 2021
- Brokers name 3 ASX shares to buy right now
- CBA (ASX:CBA) and the ASX banks just had an amazing month
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.